Yi Fan

Yi Fan

Auto-generated profile, based on publicly available information

Yi Fan

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
RPRitama Paul
Ritama Paul
JDJay F. Dorsey
Jay F. Dorsey
YFYi Fan
Yi Fan

17 February 2023 in Cell Metabolism
Verified
Journal Article
Closed access
Duo ZhangDuo Zhang
Duo Zhang
ALAlbert M. Li
Albert M. Li
GHGuanghui Hu
Guanghui Hu
MHMenggui Huang
Menggui Huang
FYFan Yang
Fan Yang
YFYi Fan
Yi Fan

8 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
FYFan Yang
Fan Yang
ZHZhenqiang He
Zhenqiang He
HDHao Duan
Hao Duan
Duo ZhangDuo Zhang
Duo Zhang
JLJuehui Li
Juehui Li
YFYi Fan
Yi Fan
Immunologically-cold tumors including glioblastoma (GBM) are refractory to checkpoint blockade therapy, largely due to extensive infiltration of immunosuppressive macrophages (Mϕs). Consistent with a pro-tumor role of IL-6 in alternative Mϕs polarization, we here show that targeting IL-6 by genetic ablation or pharmacological inhibition moderately improves T-cell infiltration into GBM and enhances mouse survival; however, IL-6 inhibition does not synergize PD-1 and CTLA-4 checkpoint blockade. Interestingly, anti-IL-6 therapy reduces CD40 expression in GBM-associated Mϕs. We identify a Stat3/HIF-1α-mediated axis, through which IL-6 executes an anti-tumor role to induce CD40 expression in Mϕs. Combination of IL-6 inhibition with CD40 stimulation reverses Mϕ-mediated tumor immunosuppression, sensitizes tumors to checkpoint blockade, and extends animal survival in two syngeneic GBM models, particularly inducing complete regression of GL261 tumors after checkpoint blockade. Thus, antibody cocktail-based immunotherapy that combines checkpoint blockade with dual-targeting of IL-6 and CD40 may offer exciting opportunities for GBM and other solid tumors.

13 December 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ZHZhongyi Hu
Zhongyi Hu
JYJiao Yuan
Jiao Yuan
MLMeixiao Long
Meixiao Long
JJJunjie Jiang
Junjie Jiang
YZYouyou Zhang
Youyou Zhang
LZLin Zhang
Lin Zhang

26 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MHMenggui Huang
Menggui Huang
Duo ZhangDuo Zhang
Duo Zhang
JWJanet Wu
Janet Wu
KXKun Xing
Kun Xing
EYEujin Yeo
Eujin Yeo
YFYi Fan
Yi Fan
Therapeutic resistance remains a persistent challenge for patients with malignant tumors. Here, we reveal that endothelial cells (ECs) acquire transformation into mesenchymal stem cell (MSC)–like cells in glioblastoma (GBM), driving tumor resistance to cytotoxic treatment. Transcriptome analysis by RNA sequencing (RNA-seq) revealed that ECs undergo mesenchymal transformation and stemness-like activation in GBM microenvironment. Furthermore, we identified a c-Met–mediated axis that induces β-catenin phosphorylation at Ser675 and Wnt signaling activation, inducing multidrug resistance–associated protein-1(MRP-1) expression and leading to EC stemness-like activation and chemoresistance. Last, genetic ablation of β-catenin in ECs overcome GBM tumor resistance to temozolomide (TMZ) chemotherapy in vivo. Combination of Wnt inhibition and TMZ chemotherapy eliminated tumor-associated ECs, inhibited GBM growth, and increased mouse survival. These findings identified a cell plasticity–based, microenvironment-dependent mechanism that controls tumor chemoresistance, and suggest that targeting Wnt/β-catenin–mediated EC transformation and stemness activation may overcome therapeutic resistance in GBM.

30 November 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
WMWenjuan Ma
Wenjuan Ma
YWYanling Wang
Yanling Wang
RZRongxin Zhang
Rongxin Zhang
FYFan Yang
Fan Yang
Duo ZhangDuo Zhang
Duo Zhang
YFYi Fan
Yi Fan